臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 246-270 / 881 (共36頁)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-08-11T03:46:52Z	Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival	Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; ZHONG-ZHE LIN; Chang M.-C.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:50Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Hsu C.-H.; Shen Y.-C.; ZHONG-ZHE LIN; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:49Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:49Z	Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma	Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:48Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y.; ZHONG-ZHE LIN; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:47Z	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma	Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:46Z	Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma	Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; ZHONG-ZHE LIN; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:46Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏	2021-08-11T03:46:45Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:43Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏	2021-08-11T03:46:43Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	ZHONG-ZHE LIN; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:42Z	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma	Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:42Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:41Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	Kuo H.-Y.; ZHONG-ZHE LIN; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:38Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2021-08-11T03:46:37Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:36Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-08-11T03:46:36Z	Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma	ZHONG-ZHE LIN; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:34Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	ZHONG-ZHE LIN; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏	2021-08-11T03:46:33Z	Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma	Chen B.-B.; Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F.
臺大學術典藏	2021-08-10T03:53:07Z	Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials	SHIH-HUNG YANG; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; Cheng A.-L.
臺大學術典藏	2021-08-10T03:53:06Z	Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy	Kuo Y.-H.; Lin C.-H.; Shau W.-Y.; Chen T.-J.; SHIH-HUNG YANG; Huang S.-M.; Hsu C.; Lu Y.-S.; Cheng A.-L.
臺大學術典藏	2021-08-10T03:53:04Z	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer	SHIH-HUNG YANG; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2021-08-10T03:53:01Z	A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study	Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T.
臺大學術典藏	2021-08-10T03:53:01Z	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients	SHIH-HUNG YANG; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H.

顯示項目 246-270 / 881 (共36頁)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52808715 線上人數 : 598 教育部委託研究計畫計畫執行:國立臺灣大學圖書館